C4 Therapeutics Inc.

NASDAQ: CCCC · Real-Time Price · USD
2.44
0.09 (3.83%)
At close: Aug 15, 2025, 12:52 PM

C4 Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
35.58M 20.76M 31.1M 45.78M
Cost of Revenue
n/a 117.71M 7.57M 2.91M
Gross Profit
35.58M -96.95M 23.52M 42.88M
Operating Income
-119.61M -139.03M -129.53M -82.13M
Interest Income
14.43M 9.81M 3.58M 387K
Pretax Income
-105.19M -131.21M -128.18M -83.89M
Net Income
-105.32M -132.49M -126.5M -86.04M
Selling & General & Admin
42.12M 42.08M 42.79M 33.25M
Research & Development
110.64M 117.71M 117.84M 94.67M
Other Expenses
2.44M n/a n/a n/a
Operating Expenses
155.2M 159.79M 160.63M 127.92M
Interest Expense
n/a 1.37M 2.22M 2.15M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
155.2M 159.79M 160.63M 127.92M
Income Tax Expense
131K 1.28M -1.68M 2.15M
Shares Outstanding (Basic)
69.37M 49.64M 48.86M 46.04M
Shares Outstanding (Diluted)
69.37M 49.64M 48.86M 46.04M
EPS (Basic)
-1.52 -2.67 -2.59 -1.87
EPS (Diluted)
-1.52 -2.67 -2.59 -1.87
EBITDA
-103.37M -122.1M -124.28M -78.84M
EBIT
-105.19M -129.84M -125.96M -81.75M
Depreciation & Amortization
1.82M 7.74M 7.57M 2.91M